{"title": "PDF", "author": "PDF", "url": "https://www.albertahealthservices.ca/assets/info/hp/cdc/if-hp-cdc-highdose-inf-vac-bio-pg-07-266.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Alberta Health Services Standard #07.26 6 September 1, 202 3 Immunization Program Standards Manual Page 1 of 4 Provincial Po pulation & Public Health Fluzone\u00ae High -Dose Influenza Vaccine Biological Page Section 7: Biological Product Information Standard #: 07.266 Created by: Provinc ial Immunization Program Standards and Quality Approved by: Provinc ial Immunization Program Standards and Quality Approval Date: August 15 , 2020 Revised: September 1, 202 3 Pasteur Biological Classification Quadrivalent , split virus inactivated influenza vaccine Indications for Provincially Funded Vaccine For persons 6 5 years of age and older Notes: ONLY persons who live, work, go to school or are visiting in Alberta are eligible to receive provincially funded influenza vaccine. Influenza Strains for the 2023 -24 Season A/Victoria/ 4897/2022 virus B/Phuket/3073/2013 (B/Yamagata lineage) -like virus Dose 0.7 mL Route I.M. Schedule 65 years of age and older: 1 dose Note: CAR T -cell therapy recipient s without a prior hist ory of HSCT who received influenza vaccine pre -CAR T -cell therapy are eligible to restart their influenza vaccine series, beginning at least 3 months post -CAR T -cell therapy. Consultation with their physician is not necessary as long as a clearance letter has been received to proceed with inactivated vaccines. For HSCT recipients who had their post -HSCT vaccine series interrupted by CAR T - cell therapy, see the following HSCT guidance: o Principles of Immunization in Hematopoietic Stem C ell Transplant Recipie nts and Solid Organ Transplant Recipients o Immunization for Adult HSCT Recipients Contraindications/ Precautions Contraindications: Persons under 65 years of age . Known hypersensitivity to any component of the vaccine excluding eg gs. Anaphylactic or othe r allergic reactions to a previous dose of influenza vaccine. Known history of Guillain Barr\u00e9 Syndrome (GBS) within 6 weeks of a previous dose of influenza vaccine. Individu als present ing with a serious acute fe brile illness o Recommendations should be provi ded for these individuals to be immunized when their symptoms have resolved . Alberta Health Services Standard #07.26 6 September 1, 202 3 Immunization Program Standards Manual Page 2 of 4 Provincial Po pulation & Public Health FLUZONE \u00ae High -Dose o Individuals with non -serious febrile illness may be immunized. Precautions : Egg allergy is no t considered a contraindication for inactivated influenza vaccine. Egg-allergic indivi duals may be safely immunized using inactivated influenza vaccine without a prior influenza vaccine skin test and with the full dose of vaccine, irrespective of a past sever e reaction to egg. They can be immuniz ed in any setting and should be kept under ob servation for 30 minutes following administration of inactivated influenza vaccine. Known history of severe oculorespiratory syndrome ( ORS ) symptoms that included lower resp iratory symptoms within 24 hours of re ceiving influenza vaccine pending consultatio n with the Medical Officer of Health to review the risks and benefits of further influenza immunization . Possible Reactions Common: Pain, redness, swelling, induration, b ruising at the Headache myalgia Uncommon: Pruritus site Fever diarrhea Cough Rare: Anaphylaxis, allergic reaction Urticaria Arthralgia Fatigue Dizziness Vomiting Flushing Pruritus Pain in extremity Guillain -Barr\u00e9 Syndrome (GB S) ORS is defined by the following symptoms occ urring within 24 hours of immunization: o bilateral red eyes and o one or more of the following respiratory symptoms (cough, wheeze, chest tightness, difficulty breathing, dif ficulty swallowing, hoarseness, sore throat) with or without facial swelling. Note: People who have an occurrence or recurrence of ORS upon immunization do not necessarily experience further episodes with future immunizations. As with any immunization, un expected or unusual side effects can occur. Refer to product monograph for more deta iled information. Pregnancy Not applicable Lactation Not applicable Composition Each 0. 7 mL dose contains: 60 mcg influenza virus hemagglutinin from each of the four virus strains Alberta Health Services Standard #07.26 6 September 1, 202 3 Immunization Program Standards Manual Page 3 of 4 Provincial Po pulation & Public Health FLUZONE \u00ae eggs Blood/Blood Products Contains no human blood/blood products. Bovine/Porcine Products Contains no bovin e or porcine products. Latex Does no t contain latex. Interchangeability Any other inactivated influenza vaccine may be interchanged for persons 65 years of age and older . Administration with Other Products May be given at the same time as other inactiv ated and live vaccines using a separa te needle and syringe for each vaccine. The sam e limb may be used if necessary, but different sites on the limb must be chosen. For co -administration with COVID -19 vaccines, refer to the \"Administration with Other Produ cts\" section in the relevant COVID -19 vaccine biological page. Appearance Clear to slightly opalescent in colour . Shake product well before administration. Storage Store at +2\u00ba C to +8\u00ba C Do not freeze. Store in original packaging when possible to protect from light. Vaccine Code FLU-HD Antigen Code FLU Licensed for Individuals 65 yea rs of age and older . Program Notes 1992 (approx.) : Influenza vaccine split virus Influenza split virus vaccine first used in Canada in approximately 1992 (Fluviral\u00ae & Vaxi grip\u00ae) 2009 October: Influenza vaccin e for H1N1 Pandemic universal program for every one six months of age and older. 2009 October: Influenza seasonal vaccine universal program to include all Albertans six months of age and older. 2015 August 12: Influenza Vaccines 2015 -2016 season: Fluad\u00ae (all years and older.), Flumist\u00ae Quadrivalent, Fluviral, Influvac\u00ae (This is the vaccine of choice for adults 18 to 64 years of age). 2016 August 29: Influenza vaccines Fluzone HD (65 years of age and older who reside in long term care beds). 2021: Influenza Vaccine HD (65 years Influenza Vaccines 2023 -2024 season: Fluzone\u00ae, FluLaval\u00ae Tetra, Fluzone\u00ae HD (65 years of age and older) Alberta Health Services Standard #07.26 6 September 1, 202 3 Immunization Program Standards Manual Page 4 of 4 Provincial Po pulation & Public Health FLUZONE \u00ae High -Dose Related Resources Alber ta Health Services Website (202 2). Influenza Immunization Influenza Immunization Health Professionals | Alberta Health Services References 1. Alberta Immunization Policy, Biological Products, Government of Alberta (202 3, August ). Influenza Vaccine High-Dose Quadri valent Vasa, P . P., Campitelli, S. H., et al. (2013). Risk of Guillain -Barr\u00e9 syndrome after seasonal influenza vaccination and infl uenz a health -care encounter: a self -contr olled study . Lancet Infectious Disease, 13, 769 -76. 3. National Advisory Committee on Immunization. Canadian immunization guide (Evergreen Edition ). Ottawa , ON: Public Health Agency of Canada . http://www.phac -aspc.gc.ca/publicat/cig -gci/index -eng.php 4. National Advisory Committee (2006 -01-03). Oculo -respiratory syndrome following influenza vaccination: Review of post -marketing sur veillance through four influenza seasons in Canada. Ottawa, ON: Public Health Agency of Canada. http://www.phac -aspc.gc.ca/publicat/ccdr -rmtc/05vol31/dr3121a -eng.php 5. National Advisory Committee on Immunization . (2023). Statement on seasonal influenza vaccine for 2023 - (2023-2024). High -Dose Quadrivalent Influenza Virus Va ccine "}